Literature DB >> 8262681

Amplification of the epidermal-growth-factor-receptor gene correlates with different growth behaviour in human glioblastoma.

J Schlegel1, A Merdes, G Stumm, F K Albert, M Forsting, N Hynes, M Kiessling.   

Abstract

The objective of our study was to determine the frequency of EGF-receptor-gene rearrangement in relation to tumour-growth behaviour in an unselected group of glioma patients. We investigated 73 glial tumours with different grades of malignancy (17 low-grade gliomas, 14 anaplastic variants, and 42 GBM) by Southern analysis, reverse transcriptase PCR (RT-PCR) amplification of mRNA, and Western analysis. An amplification of the EGF-receptor gene was present in 19/42 GBM but in only 1 anaplastic astrocytoma. By RT-PCR, 4/19 GBM with gene amplification showed a specific amino-terminal aberrant splice mutation of 801 bp in addition to undeleted mRNA. By Western analysis, 27/42 GBM showed expression of the EGF-receptor protein. Protein levels, however, varied among individual tumours. Four GBM containing an aberrant splice mutation exhibited an immunoreactive protein of 130 kDa MW in addition to the normal EGF-receptor protein p170. All GBM patients underwent surgery followed by a standard course of radiotherapy. Neuroradiological follow-up in 31/42 GBM patients consisted of bimonthly MRI examinations. There was a statistically significant difference in the mean latency period until tumour regrowth of patients suffering from GBM with and without EGF-receptor-gene amplification (9 weeks vs. 32 weeks). Our data indicate more rapid tumour regrowth kinetics of GBM with amplified EGF receptor genes in vivo.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8262681     DOI: 10.1002/ijc.2910560114

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  61 in total

1.  EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway.

Authors:  R Bonavia; M M Inda; S Vandenberg; S-Y Cheng; M Nagane; P Hadwiger; P Tan; D W Y Sah; W K Cavenee; F B Furnari
Journal:  Oncogene       Date:  2011-12-05       Impact factor: 9.867

Review 2.  Biomarkers for glioma immunotherapy: the next generation.

Authors:  Jennifer S Sims; Timothy H Ung; Justin A Neira; Peter Canoll; Jeffrey N Bruce
Journal:  J Neurooncol       Date:  2015-02-28       Impact factor: 4.130

3.  Epidermal growth factor-regulated activation of Rac GTPase enhances CD44 cleavage by metalloproteinase disintegrin ADAM10.

Authors:  Toshiyuki Murai; Takayuki Miyauchi; Toshio Yanagida; Yasushi Sako
Journal:  Biochem J       Date:  2006-04-01       Impact factor: 3.857

4.  Inhibition of FoxO1 nuclear exclusion prevents metastasis of glioblastoma.

Authors:  Jin Chen; Qin Huang; Feng Wang
Journal:  Tumour Biol       Date:  2014-04-27

5.  NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.

Authors:  David M Peereboom; Manmeet S Ahluwalia; Xiaobu Ye; Jeffrey G Supko; Sarah L Hilderbrand; Surasak Phuphanich; L Burt Nabors; Myrna R Rosenfeld; Tom Mikkelsen; Stuart A Grossman
Journal:  Neuro Oncol       Date:  2013-01-17       Impact factor: 12.300

6.  Epidermal growth factor (EGF)-enhanced vascular cell adhesion molecule-1 (VCAM-1) expression promotes macrophage and glioblastoma cell interaction and tumor cell invasion.

Authors:  Yanhua Zheng; Weiwei Yang; Kenneth Aldape; Jie He; Zhimin Lu
Journal:  J Biol Chem       Date:  2013-09-17       Impact factor: 5.157

7.  EGFR signaling-dependent inhibition of glioblastoma growth by ginsenoside Rh2.

Authors:  Shaoyi Li; Yun Gao; Weining Ma; Wenchang Guo; Gang Zhou; Tianci Cheng; Yunhui Liu
Journal:  Tumour Biol       Date:  2014-02-21

8.  Molecular genetic changes in a series of neuroepithelial tumors of childhood.

Authors:  Alessia Di Sapio; Isabella Morra; Luca Pradotto; Marilena Guido; Davide Schiffer; Alessandro Mauro
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

9.  Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization.

Authors:  Mirko H H Schmidt; Frank B Furnari; Webster K Cavenee; Oliver Bögler
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-06       Impact factor: 11.205

10.  Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.

Authors:  David M Peereboom; Dale R Shepard; Manmeet S Ahluwalia; Cathy J Brewer; Neeraj Agarwal; Glen H J Stevens; John H Suh; Steven A Toms; Michael A Vogelbaum; Robert J Weil; Paul Elson; Gene H Barnett
Journal:  J Neurooncol       Date:  2009-12-04       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.